Summary & Overview
HCPCS Q4155: Neoxflo or Clarixflo, 1 mg
HCPCS Level II code Q4155 designates a 1 mg unit of Neoxflo or Clarixflo, an ophthalmic pharmaceutical formulation. Nationally, drug-specific HCPCS Level II codes like Q4155 guide billing for clinician-administered and outpatient-dispensed medications, affecting coverage, prior authorization workflows, and payer reimbursement policies across commercial and public plans. Clear identification of the drug and unit dosage supports consistent claims processing and clinical documentation.
Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an outline of the code’s clinical role in ophthalmology, typical sites of service for administration, and the payer landscape relevant to reimbursement and coverage determinations. The publication also summarizes common billing modifiers and procedural context for service lines using this code. Where available, benchmarks and policy updates related to HCPCS Level II drug coding are discussed to help stakeholders understand payer expectations and documentation needs.
This summary is intended for a national audience of coding professionals, billing managers, and clinical leaders seeking a concise reference for HCPCS Level II code Q4155 and its role in outpatient ophthalmic drug billing and coverage pathways.
Billing Code Overview
HCPCS Level II code Q4155 represents Neoxflo or clarixflo, 1 mg, an ophthalmic therapeutic product supplied at a 1 mg dosage. This code indicates a specific drug formulation used in eye care treatments.
Service Type: Drug administration / Ophthalmic pharmaceutical
Typical Site of Service: Outpatient ophthalmology clinics, ambulatory infusion centers, or other outpatient settings where ophthalmic medications are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with symptomatic corneal edema or endothelial dysfunction being evaluated for intraoperative or postoperative intracameral use of a 1 mg formulation of a viscoelastic or adjunct named Q4155 (Neoxflo or Clarixflo, 1 mg) used during anterior segment ophthalmic procedures. The scenario often involves an ophthalmic surgeon preparing for cataract extraction with endothelial protection, Descemet membrane endothelial keratoplasty (DMEK) or Descemet stripping automated endothelial keratoplasty (DSAEK), or for management of corneal edema during intraocular manipulation.
Workflow: The patient presents to the ambulatory surgical center or hospital outpatient department for an elective anterior segment procedure. Preoperative evaluation documents indication (e.g., Fuchs endothelial dystrophy, corneal decompensation), informed consent, and planned use of an intracameral adjunct to coat/protect endothelium. On the day of surgery, the scrub team prepares the sterile single-dose Q4155 product; the surgeon documents administration of the 1 mg intracameral dose and its purpose in the operative note. Postoperative documentation includes response of the cornea, any adverse events, and billing of the HCPCS Level II code Q4155 with applicable modifiers reflecting circumstances of service, payment adjustments, or anesthesia/surgical complexity. Typical sites of service are ambulatory surgery centers (ASC), hospital outpatient departments (HOPD), or ophthalmology specialty clinics performing office-based procedures.
Coding Specifications
| Modifier | Description | When to Use |
|---|